Your patients’ stories are unique. Lucence provides insights to help guide personalized treatment so that your patients can receive the best care possible.
Our wide portfolio of tests aims to ensure that there’s a test for every need.
Our solution for treatment selection
LiquidHALLMARK is an ultrasensitive blood test designed to detect tumor-derived ctDNA and ctRNA to identify cancer-related mutations and biomarkers with a single blood draw.
LiquidHALLMARK is currently Medicare covered under CPT code 0571U for qualifying patients with advanced cancer.
Lucence is collaborating with Mayo Clinic Laboratories to expand access to LiquidHALLMARK testing.
LiquidHALLMARK has been added to Mayo Clinic Laboratories test catalog.
Access our Portal for Healthcare Providers
-
All your patients test results right at your fingertips
-
Easily place orders online for LiquidHALLMARK testing
-
Request a home blood draw for your patients who may face a barrier to care with our mobile phlebotomy services
-
Submit questions, order kits, or keep up to date on the latest Lucence news
Email us at support.us@lucence.com to sign up.
Ordering Process
Report ready in median 7 working days from sample acceptance
Watch our LiquidHALLMARK report guide video.
Frequently Asked Questions
LiquidHALLMARK combines ctDNA and ctRNA analysis, enabling high sensitivity for detecting fusions and other alterations often missed by ctDNA-only panels.
In our LIQUIK study, LiquidHALLMARK ctDNA + ctRNA detected 15.6% (52/68 vs 45/68) additional tissue-confirmed, NCCN guideline-recommended biomarkers for NSCLC than the ctDNA-only FDA-approved test.
Read the full publicationLiquidHALLMARK is a laboratory-developed test (LDT), which means it's validated and performed in our CLIA-certified, CAP-accredited lab.
Unlike an FDA approved test, an LDT allows us to update the assay rapidly as new biomarkers emerge or new clinical evidence comes in, which is critical in a fast-moving field like oncology.
Among other scenarios, FDA approval is typically pursued when the test is being used as a companion diagnostic, where it must match a specific drug indication, but that also locks the design and limits flexibility.LiquidHALLMARK is designed to detect guideline-recommended cancer biomarkers - including RNA fusions that are often missed by ctDNA-only liquid biopsy tests.
LiquidHALLMARK can be used to inform therapy selection, clinical trial matching and monitoring for therapy adjustments.
The test may be useful when tissue biopsy is not feasible (insufficient tissue quantity, tumor is inaccessible for biopsy, etc.).LiquidHALLMARK is currently covered under Medicare under PLA code 0571U for qualifying patients with advanced cancer.
Lucence welcomes all insurance plans including commercial plans, Medicare, and Medicaid.
We provide claims support including billing the patient’s insurance and supporting the appeals process. Once the claim is processed, we will bill the patient for any required cost-sharing amounts. If the claim is denied or the patient is a self-paying patient, we will issue an invoice at our self-pay rate.
If the patient meets certain household income and other eligibility criteria, the patient may qualify for our Patient Assistance Program, which limits their our-of-pocket cost to $95.
Download Insurance Coverage and Billing Information
References:
-
Samol J, et al. JCO Precis. Oncol. 2025; 9: e2500181.
-
Heeke et al. JTO Clin Res Rep. 2025: 100795.
Our strategic collaborator
Our research collaborators
